Huace Testing 2026 Interim Report Shows All Divisions Positive, Overseas Up 63%
Huace Testing has released its 2026 interim report, revealing positive growth across all business divisions. The pharmaceutical and medical services segment showed particularly strong momentum. Domestic business expanded by 12% year-on-year, while overseas business surged 63%. The results highlight the company's balanced development across domestic and international operations.
In its 2026 interim report, Huace Testing announced that all business divisions achieved positive growth during the first half of the year. The pharmaceutical and medical services segment saw notably significant growth, although the company did not disclose a specific figure. Domestic business grew 12% year-on-year, while overseas business grew 63%.